Form 4: Axsome Therapeutics Director, Mark Coleman, Reports Stock Option Grant

Mark Coleman, a director at Axsome Therapeutics, reported the acquisition of stock options exercisable for 5,799 shares of common stock.

Summary

• On June 7, 2024, Mark Coleman, a director of Axsome Therapeutics, Inc., was granted stock options to purchase 5,799 shares of the company's common stock.
• The exercise price of the stock options is $73.90.
• The options vest in full on June 7, 2025, one year after the grant date, and expire on June 7, 2034.
• Following the transaction, Coleman directly owns 5,799 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant, which is a common practice in executive compensation.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards increasing the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant is typical for a director at a company of Axsome's size and stage of development.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates